TrialClinical trialPHN-02852026-10-27 19:00 CT
A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus
Source · ClinicalTrials.gov: peptide AND aging
TLDR
ClinicalTrials.gov lists a study of enicepatide (CT-388) in participants with overweight or obesity and Type 2 diabetes as completed. The randomized, double-blind, placebo-controlled trial evaluated efficacy and safety across three dose levels; the excerpt provides no results.
01—Key points
- 01The multicenter trial used a parallel-group, dose-finding design.
- 02Participants had overweight or obesity and Type 2 diabetes.
- 03Completion status is reported, but efficacy and safety findings are not included.
Why it matters Editorial
The listing documents completion of an enicepatide trial but does not establish whether the treatment was effective or safe.
Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.
No related news yet.